Egenesis Stock
HealthTechLooking to sell Egenesis stock or options?
Egenesis is developing a gene editing and genome engineering platform aimed at revolutionizing solid organ and therapeutic cell transplantation for treating life-threatening illnesses. The company's platform provides gene editing techniques to create human-compatible organ tissue cells and spearheads programs in kidney and islet cell transplantation, allowing patients to recover and maintain a healthy life.
Alta Partners, SymBiosis Capital Management, Samsara BioCapital, Fan Ventures, Polaris Partners, HBM Partners, DaVita, Farallon Capital Management, T1D Fund, Osage University Partners, Eisai Innovation, Irving Investors, HBM Healthcare Investments, Codon Capital, Alexandria Venture Investments, The Invus Group, Altium Capital, E Squared Capital Management, Parkwood, Khosla Ventures, LifeSci Venture Partners, Catalio Capital Management, Lux Capital, Wellington Partners, Altium Capital Management.